Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer.
Hasegawa H, Taniguchi H, Nakamura Y, Kato T, Fujii S, Ebi H, Shiozawa M, Yuki S, Masuishi T, Kato K, Izawa N, Moriwaki T, Oki E, Kagawa Y, Denda T, Nishina T, Tsuji A, Hara H, Esaki T, Nishida T, Kawakami H, Sakamoto Y, Miki I, Okamoto W, Yamazaki K, Yoshino T. Hasegawa H, et al. Among authors: yuki s. Cancer Sci. 2021 Jan;112(1):314-322. doi: 10.1111/cas.14693. Epub 2020 Nov 20. Cancer Sci. 2021. PMID: 33075166 Free PMC article.
[Second-line chemotherapy for colorectal cancer].
Komatsu Y, Sogabe S, Kawamoto Y, Iwanaga I, Uehata Y, Yuki S, Asaka M. Komatsu Y, et al. Among authors: yuki s. Gan To Kagaku Ryoho. 2009 May;36(5):721-5. Gan To Kagaku Ryoho. 2009. PMID: 19461170 Japanese.
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Shitara K, Yuki S, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Inaba Y, Tajika M, Kawai H, Yamaura H, Kato M, Yamazaki K, Komatsu Y, Muro K. Shitara K, et al. Among authors: yuki s. Invest New Drugs. 2012 Apr;30(2):787-93. doi: 10.1007/s10637-010-9615-z. Epub 2010 Dec 22. Invest New Drugs. 2012. PMID: 21174225 Clinical Trial.
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
Shitara K, Ura T, Matsuo K, Takahari D, Yokota T, Yuki S, Yoshida M, Utsunomiya S, Sato Y, Yamaura H, Kato M, Inaba Y, Tajika M, Kawai H, Yamazaki K, Komatsu Y, Muro K. Shitara K, et al. Among authors: yuki s. Eur J Cancer. 2011 Dec;47(18):2673-80. doi: 10.1016/j.ejca.2011.05.015. Epub 2011 Jun 7. Eur J Cancer. 2011. PMID: 21652203
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Komatsu Y, Yoshino T, Yamazaki K, Yuki S, Machida N, Sasaki T, Hyodo I, Yachi Y, Onuma H, Ohtsu A. Komatsu Y, et al. Among authors: yuki s. Invest New Drugs. 2014 Jun;32(3):473-80. doi: 10.1007/s10637-013-0056-3. Epub 2013 Dec 15. Invest New Drugs. 2014. PMID: 24337768 Free PMC article. Clinical Trial.
177 results